SHLD1

SHLD1 is a subunit of the shieldin complex (SHLD1–SHLD2–SHLD3–REV7) that functions downstream of 53BP1–RIF1 to protect DNA double-strand break ends from nucleolytic resection, thereby promoting non-homologous end-joining over homologous recombination and enabling immunoglobulin class-switch recombination (PMID:30022168, PMID:30022158, PMID:35764636). SHLD1 serves as the primary recruiter of the CST (CTC1–STN1–TEN1) complex to DSBs, where CST–Pol α-primase performs fill-in synthesis to counteract resection; a SHLD1 mutant unable to bind CST is non-functional in BRCA1-deficient cells unless CST is artificially tethered (PMID:35027730). Shieldin assembly depends on a REV7 conformational heterodimer (closed/open) scaffolded by SHLD3, and the complex is disassembled by the AAA+ ATPase TRIP13, which converts closed-REV7 to open-REV7, providing a regulated mechanism for switching repair pathway choice (PMID:32332881, PMID:33597306). Loss of SHLD1 restores homologous recombination and confers PARP inhibitor resistance in BRCA1-deficient cells, while its transcriptional output—controlled by THAP1–YY1–HCF1 at the promoter—is rate-limiting for DSB repair pathway balance (PMID:30022119, PMID:33857404).

1. 2018 High

   Identification of SHLD1 as a shieldin subunit resolved how 53BP1–RIF1 signaling is transduced to the DNA end to block resection and promote NHEJ, filling a gap between upstream chromatin readers and the effector machinery.

   Evidence CRISPR screens, co-immunoprecipitation, laser micro-irradiation, and epistasis in human and mouse cells across four independent laboratories

   PMID:30022119 PMID:30022158 PMID:30022168 PMID:30046110 PMID:30154076

   Open questions at the time

   • Direct structural role of SHLD1 within the complex was not resolved
   • Whether SHLD1 itself contacts DNA was unclear
   • Mechanism by which shieldin blocks nucleases not established
2. 2018 High

   Demonstration that SHLD2's OB-fold domains bind ssDNA and that shieldin recruits CST–Pol α for fill-in synthesis established a two-step end-protection mechanism: physical capping of ssDNA plus resynthesis.

   Evidence In vitro ssDNA binding assays, OB-fold mutagenesis, CST co-IP, BrdU incorporation at DSBs

   PMID:30022158 PMID:30022168 PMID:30046110 PMID:30254264

   Open questions at the time

   • Whether SHLD1 or SHLD2 directly contacts CST was not determined
   • Structural basis of ssDNA recognition was incomplete
3. 2018 High

   Loss-of-function studies showed SHLD1 is required for class-switch recombination and PARP inhibitor sensitivity in BRCA1-deficient cells, establishing shieldin as a clinical determinant of therapy resistance.

   Evidence CRISPR knockouts in B cells and BRCA1-null cancer cells, CSR assays, PARP inhibitor dose-response

   PMID:30022119 PMID:30022158 PMID:30022168 PMID:30046110

   Open questions at the time

   • Whether shieldin loss occurs in patient tumors conferring resistance was not shown
   • Relative contribution of CST recruitment vs. ssDNA capping was unclear
4. 2020 High

   Crystal structures of the SHLD3–REV7–SHLD2 ternary complex revealed that shieldin assembly requires an unexpected closed/open REV7 conformational heterodimer, explaining how REV7 acts as a structural hub rather than a simple adaptor.

   Evidence X-ray crystallography, REV7 dimer interface mutagenesis, NHEJ reporter assays

   PMID:32332881

   Open questions at the time

   • SHLD1 was not present in the crystal structure
   • How the heterodimer is initially formed in vivo was not established
5. 2020 High

   Discovery that TRIP13 ATPase disassembles shieldin by converting closed-REV7 to open-REV7 provided the first regulated off-switch for the 53BP1 end-protection pathway, explaining how cells can toggle from NHEJ to HR.

   Evidence Co-IP, REV7 conformation-specific assays, TRIP13 overexpression/knockdown with HDR/NHEJ reporters

   PMID:31915374

   Open questions at the time

   • Temporal regulation of TRIP13 activity at DSBs was not resolved
   • Whether TRIP13-mediated disassembly is cell-cycle regulated was not shown
6. 2021 High

   Cryo-EM structures of the SHLD2–SHLD3–REV7–TRIP13 complex defined the mechanical basis of disassembly: TRIP13 threads the C-REV7 N-terminus through its central pore via ATP-driven rotary translocation, providing an atomic-level model for shieldin regulation.

   Evidence Cryo-EM, crystal structures of sub-complexes, ATPase mutagenesis, in vitro disassembly assays

   PMID:33597306

   Open questions at the time

   • SHLD1 position in the full complex was still not structurally resolved
   • In vivo dynamics of the disassembly cycle were not measured
7. 2021 High

   Identification of THAP1–YY1–HCF1 as transcriptional regulators binding the SHLD1 promoter established that SHLD1 expression level is rate-limiting for DSB repair pathway choice, adding a transcriptional layer of regulation above the post-translational TRIP13 switch.

   Evidence Promoter ChIP, transcription factor binding assays, SHLD1 expression modulation with PARPi/cisplatin sensitivity readouts, mouse embryonic lethality rescue

   PMID:33857404

   Open questions at the time

   • Signals that modulate THAP1–YY1 occupancy at the SHLD1 promoter were not identified
   • Whether this transcriptional control is cancer-relevant was not tested
8. 2022 High

   Mutational dissection of SHLD1 demonstrated that its CST-binding activity is the essential effector function at BRCA1-deficient DSBs, while CST-independent roles exist at telomeres and CSR loci with intrinsic CST recognition sequences.

   Evidence SHLD1 CST-binding mutant complementation, forced CST tethering rescue, radial chromosome assay, BrdU incorporation

   PMID:35027730 PMID:40178294

   Open questions at the time

   • Structural basis of the SHLD1–CST interaction was not determined
   • Whether additional SHLD1 effector interactions exist remains open
9. 2022 High

   Genetic separation of SHLD1's roles showed it is essential for CSR but dispensable for V(D)J recombination, clarifying that shieldin-mediated end protection is required specifically at AID-induced breaks for orientation-specific joining.

   Evidence SHLD1 knockout B cells, parallel V(D)J and CSR assays, end-resection quantification, joining orientation analysis

   PMID:35764636

   Open questions at the time

   • Why V(D)J breaks are shieldin-independent was not mechanistically explained
   • Whether other factors substitute for shieldin at V(D)J breaks is unknown
10. 2025 Medium

    In the absence of SHLD1-mediated end protection, CSR is rerouted to a Pol θ-dependent alternative pathway characterized by resection, inversions, and microhomology usage, establishing that shieldin suppresses mutagenic repair in G1-to-S phase.

    Evidence SHLD1/XRCC4 double-knockout primary B cells, CSR junction sequencing, Pol θ epistasis

    PMID:41298353

    Open questions at the time

    • Single-study finding awaiting independent replication
    • Whether Pol θ-dependent CSR contributes to lymphomagenesis was not tested
    • Cell-cycle specificity of the shieldin–Pol θ antagonism was inferred but not directly demonstrated

• The position of SHLD1 within the fully assembled shieldin–CST complex remains structurally unresolved, and the molecular determinants of the SHLD1–CST interface have not been defined at atomic resolution.
• No high-resolution structure includes SHLD1
• SHLD1–CST binding interface not mapped at residue level
• Whether SHLD1 has additional effector partners beyond CST is unknown